Last checked at 25 Jul 2019 15:31
Polarean Imaging Plc
("Polarean" or the "Company")
Result of AGM
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
Enquiries:
Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | ||
Richard Hullihen, Chief Executive Officer | Via Walbrook PR | ||
Richard Morgan, Chairman Chuck Osborne, Chief Financial Officer | |||
| |||
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 | ||
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) | |||
Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | ||
Paul McManus / Anna Dunphy
| Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001
| ||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.